Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density Affymetrix 10K single nucleotide polymorphism mapping array

Neoplasia

Volumn 10, Issue 7, 2008, Pages 634-642

  Toma, Marieta I ^a,b   Grosser, Marianne ^a   Herr, Alexander ^a   Aust, Daniela E ^a   Meye, Axel ^a   Hoefling, Christian ^a   Fuessel, Susanne ^a   Wuttig, Daniela ^a   Wirth, Manfred P ^a   Baretton, Gustavo B ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; FRAGILE HISTIDINE TRIAD PROTEIN; GENOMIC DNA; LEUCINE RICH REPEAT KINASE 2; PARKIN; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER GENETICS; CARCINOGENESIS; CHROMOSOME 1; CHROMOSOME 14Q; CHROMOSOME 3P; CHROMOSOME 5Q; CHROMOSOME 6; CHROMOSOME 7; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME NUMBER; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; DNA MICROARRAY; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION; GENE LOCUS; GENE NUMBER; GENETIC DISORDER; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MICROARRAY ANALYSIS; NORMAL HUMAN; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; QUANTITATIVE GENETICS; QUANTITATIVE HISTOCHEMISTRY; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 45849149191     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08160     Document Type: Article

References (35)

1. Higgins JP, Shinghal R, Gill H, Reese JH, Terris M, Cohen RJ, Fero M, Pollack JR, van de Rijn M, and Brooks JD (2003). Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 162, 925-932.
2. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, and Neish AS (2001). Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 158, 1639-1651.
3. Clifford SC, Prowse AH, Affara NA, Buys CH, and Maher ER (1998). Inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear tumourigenesis. Genes Chromosomes Cancer 22, 200-209.
4. Martinez A, Fullwood P, Kondo K, Kishida T, Yao M, Maher ER, and Latif F (2000). Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis. Mol Pathol 53, 137-144.
5. Higgins JP (2006). Gene array studies in renal neoplasia. ScientificWorldJournal 6, 502-511.
6. Kondo K, Yao M, Yoshida M, Kishida T, Shuin T, Miura T, Moriyama M, Kobayashi K, Sakai N, Kaneko S, et al. (2002). Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 34, 58-68.
7. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, et al. (1994). Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7, 85-90.
8. Thrash-Bingham CA, Salazar H, Freed JJ, Greenberg RE, and Tartof KD (1995). Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res 55, 6189-6195.
9. Kardas I, Mrozek K, Babinska M, Krajka K, Hadaczek P, Lubinski J, Roskiewicz A, Kuziemska E, and Limon J (2005). Cytogenetic and molecular findings in 75 clear cell renal cell carcinomas. Oncol Rep 13, 949-956.
10. Moch H, Presti JC Jr, Sauter G, Buchholz N, Jordan P, Mihatsch MJ, and Waldman FM (1996). Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res 56, 27-30.
11. Mitsumori K, Kittleson JM, Itoh N, Delahunt B, Heathcott RW, Stewart JH, McCredie MR, and Reeve AE (2002). Chromosome 14q LOH in localized clear cell renal cell carcinoma. J Pathol 198, 110-114.
12. Kaku H, Ito S, Ebara S, Ouchida M, Nasu Y, Tsushima T, Kumon H, and Shimizu K (2004). Positive correlation between allelic loss at chromosome 14q24-31 and poor prognosis of patients with renal cell carcinoma. Urology 64, 176-181.
13. Alimov A, Sundelin B, Wang N, Larsson C, and Bergerheim U (2004). Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival. Int J Oncol 25, 179-185.
14. Nagao K, Yamaguchi S, Matsuyama H, Korenaga Y, Hirata H, Yoshihiro S, Fukunaga K, Oba K, and Naito K (2005). Allelic loss of 3p25 associated with alterations of 5q22.3 approximately q23.2 may affect the prognosis of conventional renal cell carcinoma. Cancer Genet Cytogenet 160, 43-48.
15. Janne PA, Li C, Zhao X, Girard L, Chen TH, Minna J, Christiani DC, Johnson BE, and Meyerson M (2004). High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 23, 2716-2726.
16. Zheng HT, Peng ZH, Li S, and He L (2005). Loss of heterozygosity analyzed by single nucleotide polymorphism array in cancer. World J Gastroenterol 11, 6740-6744.
17. Lam CW, To KF, and Tong SF (2006). Genome-wide detection of allelic imbalance in renal cell carcinoma using high-density single-nucleotide polymorphism microarrays. Clin Biochem 39, 187-190.
18. Herr A, Grutzmann R, Matthaei A, Artelt J, Schrock E, Rump A, and Pilarsky C (2005). High-resolution analysis of chromosomal imbalances using the Affymetrix 10K SNP genotyping chip. Genomics 85, 392-400.
19. Pfaffl MW (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, 2002-2007.
20. Lindblad-Toh K, Tanenbaum DM, Daly MJ, Winchester E, Lui WO, Villapakkam A, Stanton SE, Larsson C, Hudson TJ, Johnson BE, et al. (2000). Loss-of-heterozygosity analysis of small-cell lung carcinoma using single-nucleotide polymorphism arrays. Nat Biotechnol 18, 1001-1005.
21. Hoque MO, Lee CC, Cairns P, Schoenberg M, and Sidransky D (2003). Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 63, 2216-2222.
22. Primdahl H, Wikman FP, von der Maase H, Zhou XG, Wolf H, and Orntoft TF (2002). Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst 94, 216-223.
23. Wilhelm M, Veltman JA, Olshen AB, Jain AN, Moore DH, Presti JC Jr, Kovacs G, and Waldman FM (2002). Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer. Cancer Res 62, 957-960.
24. Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Harris AL, and Banham AH (2006). Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1α expression. Mod Pathol 19, 9-16.
25. Fox SB, Brown P, Han C, Ashe S, Leek RD, Harris AL, and Banham AH (2004). Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res 10, 3521-3527.
26. Banham AH, Beasley N, Campo E, Fernandez PL, Fidler C, Gatter K, Jones M, Mason DY, Prime JE, Trougouboff P, et al. (2001). The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 61, 8820-8829.
27. Strefford JC, Stasevich I, Lane TM, Lu YJ, Oliver T, and Young BD (2005). A combination of molecular cytogenetic analyses reveals complex genetic alterations in conventional renal cell carcinoma. Cancer Genet Cytogenet 159, 1-9.
28. Presti JC Jr, Wilhelm M, Reuter V, Russo P, Motzer R, and Waldman F (2002). Allelic loss on chromosome 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 167, 1464-1468.
29. Schraml P, Struckmann K, Bednar R, Fu W, Gasser T, Wilber K, Kononen J, Sauter G, Mihatsch MJ, and Moch H (2001). CDKN2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas. Am J Pathol 158, 593-601.
30. Zhao J, Yart A, Frigerio S, Perren A, Schraml P, Weisstanner C, Stallmach T, Krek W, and Moch H (2007). Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene. Oncogene 26, 3440-3449.
31. Sudarshan S, Pinto PA, Neckers L, and Linehan WM (2007). Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer - a distinct form of hereditary kidney cancer. Nat Clin Pract Urol 4, 104-110.
32. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Denefle P, Wood NW, et al. (2000). Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 341, 1560-1567.
33. West AB, Lockhart PJ, O'Farell C, and Farrer MJ (2003). Identification of a novel gene linked to parkin via a bi-directional promoter. J Mol Biol 326, 11-19.
34. Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Garate L, Montiel-Duarte C, Artieda P, Cordeu L, Lahortiga I, Calasanz MJ, et al. (2006). Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 118, 1945-1953.
35. Seng TJ, Low JS, Li H, Cui Y, Goh HK, Wong ML, Srivastava G, Sidransky D, Califano J, Steenbergen RD, et al. (2007). The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene 26, 934-944.